Aurinia Pharmaceuticals Inc. AUPH
16.56 USD +0.42 (+2.60%)
At closeNov 3, 2026, 4:01 PM EST
16.56 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
16.13 Day range 16.73
13.33 52-week range 19.25
- YTD
- +3.82%
- 1 year
- +25.74%
- Market cap
- 2.22B
- Revenue (ttm)
- 321.74M
- Profit margin
- 97.68%
- EPS (ttm)
- 2.28
- Shares out
- 134.00M
- P/E ratio
- 7.26
- Forward P/E
- 14.28
- YTD return
- +3.82%
- 1-year return
- +25.74%
- Volume
- 1.18M
- Avg volume
- 917.95K
- Open
- 16.15
- Previous close
- 16.14
- Day's range
- 16.13 – 16.73
- 52-week range
- 13.33 – 19.25
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 18.29 (+10.4%)
- Earnings date
- Feb 25, 2027
YTD +1.21 (+7.88%)
Key statistics
- Enterprise value
- 1.73B
- PEG ratio
- 0.00
- Price / sales
- 6.90
- Price / book
- 3.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.90%
- Free cash flow
- 140.48M
- Total cash
- 486.53M
- Total debt
- 58.66M
- Return on equity
- 61.42%
- Short % of float
- 6.41%
- 50-day average
- 16.48
- 200-day average
- 15.65
Analyst view
Consensus: buy
Buy
Price target (mean) 18.29 +10.4% upside
Now 16.56
- Target (low)
- 16.00
- Target (mean)
- 18.29
- Target (high)
- 21.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.214.
Financials — quick view
AUPH Revenue — quarterly 83.70M
AUPH Net income — quarterly 31.70M
AUPH EPS — quarterly 0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.19 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.22 | 0.23 | +0.01 | +4.55% |
| Aug 6, 2026 | Jun 30, 2026 | 0.24 | 0.28 | +0.04 | +16.67% |
| May 7, 2026 | Mar 31, 2026 | 0.18 | 0.25 | +0.07 | +38.89% |
| Feb 26, 2026 | Dec 31, 2025 | 0.21 | 0.26 | +0.05 | +23.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.16 | 0.23 | +0.07 | +43.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 3, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Nov 7, 2025 | Jefferies | up | Hold | Buy |
| Nov 5, 2025 | RBC Capital | down | Outperform | Sector Perform |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- auriniapharma.com
News
Why Is Teva Stock Trading Lower on Monday? 
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $18 
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates 
Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est - Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress 
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline 
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term 
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term - TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
Your note
Sign in to keep a note on AUPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY JEFFREY ALLEN | Director | Stock Award(Grant) | Nov 20, 2024 | 25,491 |
| COLE RYAN | Chief Operating Officer | Stock Award(Grant) | May 17, 2026 | 116,144 |
| DONLEY MATTHEW MAXWELL | Chief Operating Officer | Stock Award(Grant) | Feb 26, 2026 | 680,299 |
| GREENLEAF PETER S | Chief Executive Officer | Stock Award(Grant) | Feb 26, 2026 | 1,840,380 |
| HEARNE MICHAEL S. | Chief Financial Officer | Stock Award(Grant) | May 17, 2026 | 116,144 |
| JAYNE DAVID ROLAND WALKER | Director | Stock Award(Grant) | Nov 20, 2024 | 56,499 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.73% | 13,044,106 | 216.01M | Jun 29, 2026 |
| Blackrock Inc. | 6.11% | 8,193,085 | 135.68M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.19% | 5,619,401 | 93.06M | Jun 29, 2026 |
| NEA Management Company, LLC | 2.96% | 3,969,834 | 65.74M | Jun 29, 2026 |
| Two Sigma Investments, LP | 2.59% | 3,467,514 | 57.42M | Jun 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 2.44% | 3,264,062 | 54.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.31% | 3,089,770 | 51.17M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.97% | 1,305,257 | 21.62M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.83% | 1,116,707 | 18.49M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.68% | 917,683 | 15.20M | Sep 29, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.51% | 683,824 | 11.32M | Aug 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs U.S. Tax-Managed Equity Fund | 0.40% | 541,443 | 8.97M | Jun 29, 2026 |